1. Home
  2. SNTI vs RFL Comparison

SNTI vs RFL Comparison

Compare SNTI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$1.02

Market Cap

53.6M

Sector

Health Care

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.19

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTI
RFL
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
53.6M
54.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SNTI
RFL
Price
$1.02
$1.19
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
288.7K
93.9K
Earning Date
03-19-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,029,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$150.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.63
52 Week Low
$1.02
$1.12
52 Week High
$5.10
$3.19

Technical Indicators

Market Signals
Indicator
SNTI
RFL
Relative Strength Index (RSI) 37.65 43.14
Support Level $1.04 $1.14
Resistance Level $1.19 $1.25
Average True Range (ATR) 0.06 0.06
MACD 0.02 -0.00
Stochastic Oscillator 10.53 25.00

Price Performance

Historical Comparison
SNTI
RFL

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: